Zentalis Pharmaceuticals Dirección
Dirección controles de criterios 1/4
El CEO de Zentalis Pharmaceuticals' es Kim Blackwell , nombrado en May 2022, tiene una permanencia de 1.92 años. compensación anual total es $36.61M, compuesta por 1.2% salario y 98.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.071% de las acciones de la empresa, por valor de $657.08K. La antigüedad media del equipo directivo y de la junta directiva es de 0.4 años y 3.2 años, respectivamente.
Información clave
Kim Blackwell
Chief Executive Officer (CEO)
US$36.6m
Compensación total
| Porcentaje del salario del CEO | 1.2% |
| Permanencia del CEO | 1.9yrs |
| Participación del CEO | 0.07% |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 3.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29
Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Zentalis initiates multiple early-stage clinical trials for cancer
Jan 06Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Nov 28
Zentalis: An Interesting Small Molecule Oncology Developer For Your Watchlist
Nov 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$292m |
| Sep 30 2023 | n/a | n/a | -US$286m |
| Jun 30 2023 | n/a | n/a | -US$285m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$37m | US$432k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$232m |
| Jun 30 2022 | n/a | n/a | -US$182m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$793k | n/a | -US$159m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$179m |
| Mar 31 2021 | n/a | n/a | -US$152m |
| Dec 31 2020 | US$1m | n/a | -US$118m |
Compensación vs. Mercado: La compensación total de Kim($USD36.61M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.47M).
Compensación vs. Ingresos: La compensación de Kim ha aumentado mientras la empresa no es rentable.
CEO
Kim Blackwell (53 yo)
1.9yrs
Permanencia
US$36,614,376
Compensación
Dr. Kimberly Lynn Blackwell, M.D. also known as Kim, serves as Scientific Co-Founder at Cereius, Inc. She serves as an Independent Director at Century Therapeutics, Inc. since June 2021. Dr. Blackwell has...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$36.61m | 0.071% $ 559.0k | |
| Co-Founder | 1.9yrs | US$10.63m | 0.34% $ 2.7m | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | US$6.48m | 0.0097% $ 76.1k | |
| VP of Finance & Interim Principal Accounting Officer | no data | sin datos | 0.050% $ 392.2k | |
| Chief Scientific Officer | less than a year | sin datos | 0.0035% $ 27.5k | |
| Chief Medical Officer & Director | less than a year | sin datos | sin datos | |
| Chief Strategy Officer | less than a year | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| Executive Vice President of Clinical Development | less than a year | sin datos | sin datos |
0.4yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ZNTL no se considera experimentado ( 0.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$36.61m | 0.071% $ 559.0k | |
| Co-Founder | 9.3yrs | US$10.63m | 0.34% $ 2.7m | |
| Chief Medical Officer & Director | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.6yrs | US$1.11m | 0.010% $ 79.7k | |
| Independent Chairman of the Board | 4.3yrs | US$786.05k | 0.18% $ 1.4m | |
| Independent Director | 3.2yrs | US$666.43k | 0.031% $ 241.3k | |
| Independent Director | 6.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos |
3.2yrs
Permanencia media
52.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ZNTL se considera experimentada (3.2 años de antigüedad promedio).